Analytical Data
-
Gene name
CD1B
- Application
-
Alternative Names
CD1B；T-cell surface glycoProtein CD1b
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P29016
-
Expression Region
18-303aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMSEHAFQ GPTSFHVIQT SSFTNSTWAQ TQGSGWLDDL QIHGWDSDSG TAIFLKPWSK GNFSDKEVAE LEEIFRVYIF GFAREVQDFA GDFQMKYPFE IQGIAGCELH SGGAIVSFLR GALGGLDFLS VKNASCVPSP EGGSRAQKFC ALIIQYQGIM ETVRILLYET CPRYLLGVLN AGKADLQRQV KPEAWLSSGP SPGPGRLQLV CHVSGFYPKP VWVMWMRGEQ EQQGTQLGDI LPNANWTWYL RATLDVADGE AAGLSCRVKH SSLEGQDIIL YWRNPTSIGS
-
Molecular Weight
34 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD1B is a member of the CD1 family of molecules that plays a crucial role in the immune response by presenting lipid antigens to T cells, particularly invariant natural killer T (iNKT) cells. Research into CD1B recombinant proteins has gained traction due to their potential therapeutic applications, particularly in vaccine development and immunotherapy. These proteins are utilized to better understand the structural and functional properties of CD1B, including its ligand-binding capacity and interaction mechanisms with T cell receptors. By generating recombinant CD1B molecules, scientists can explore the antigen presentation pathways and the corresponding immune responses elicited by different lipid antigens. Furthermore, CD1B's unique ability to present non-peptidic antigens represents a significant departure from traditional peptide-based vaccines, highlighting the need for innovative strategies in combating various diseases, including infections and cancer. Overall, the study of CD1B recombinant proteins is pivotal for uncovering novel immunological pathways and designing effective approaches to harness the immune system for therapeutic purposes.
